Truist Financial set a $90.00 price target on Edwards Lifesciences shares, and TD Cowen reaffirmed its buy rating and raised the price objective.
5 reports, 3 independent
Updated Sep 14
Gone quiet
- Reports
- 5
- Developments
- 1
- Repetition
- 80%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Truist Financial set a $90.00 price target on Edwards Lifesciences shares, and TD Cowen reaffirmed its buy rating and raised the price objective.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Edwards Lifesciences
American medical technology company
-
Truist Financial
American bank holding company, formerly known as BB&T Corporation
- MarketBeat aggregates data on Inventiva's stock, and Truist Financial has started coverage of the company.
- Bank of America boosted its price target and gave a buy rating for Guardian Pharmacy Services, Inc. on September 15, 2026. Truist Financial also boosted its target price and gave a buy rating on the same day.
-
TD Cowen
American investment bank
Related events
- Truist Financial boosted price target and gave buy rating, and TD Cowen lifted target price and gave buy rating for Encompass Health.
- TD Cowen issued a buy rating and price target for Evolv Technologies Holdings, Inc.
- TD Cowen raised its price target on Exelixis shares on August 30, 2026.
- TD Cowen raised its price target on Victoria's Secret, with MarketBeat reporting the stock's average rating.
- TD Cowen increased its target price to $3.00, while Jefferies Financial Group was involved in a rating update for Plug Power, with MarketBeat aggregating the consensus data.